Free Trial

CRISPR Therapeutics (CRSP) Competitors

CRISPR Therapeutics logo
$54.82 +3.63 (+7.09%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$55.40 +0.58 (+1.06%)
As of 06:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, ILMN, and GMAB

Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), Illumina (ILMN), and Genmab A/S (GMAB). These companies are all part of the "med - biomed/gene" industry.

CRISPR Therapeutics vs. Its Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

CRISPR Therapeutics currently has a consensus price target of $71.75, suggesting a potential upside of 30.88%. Allogene Therapeutics has a consensus price target of $8.44, suggesting a potential upside of 603.70%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53
Allogene Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Allogene Therapeutics. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 1 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.46 beat Allogene Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Allogene Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$37.31M126.89-$366.25M-$4.52-12.13
Allogene Therapeutics$20K13,123.80-$257.59M-$1.23-0.98

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-1,023.64% -20.08% -17.13%
Allogene Therapeutics N/A -52.98%-41.28%

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRSP vs. The Competition

MetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.42B$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E Ratio-12.1320.8027.0020.11
Price / Sales126.89286.27429.45119.84
Price / CashN/A41.1936.8257.86
Price / Book2.427.487.985.56
Net Income-$366.25M-$55.04M$3.16B$248.40M
7 Day Performance6.10%2.44%2.38%4.67%
1 Month Performance30.24%1.90%2.17%6.64%
1 Year Performance-0.38%4.35%33.80%21.31%

CRISPR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRSP
CRISPR Therapeutics
2.9811 of 5 stars
$54.82
+7.1%
$71.75
+30.9%
+3.0%$4.42B$37.31M-12.13460Analyst Forecast
ALLO
Allogene Therapeutics
2.9899 of 5 stars
$1.15
-2.5%
$8.44
+634.3%
-46.4%$251.54M$20K-0.93310
AXSM
Axsome Therapeutics
4.7367 of 5 stars
$104.08
+0.7%
$172.33
+65.6%
+29.6%$5.12B$385.69M-18.04380
BEAM
Beam Therapeutics
2.6451 of 5 stars
$17.14
+2.0%
$48.75
+184.4%
-14.9%$1.72B$63.52M-3.72510
EDIT
Editas Medicine
4.1755 of 5 stars
$2.25
-1.3%
$4.70
+108.9%
-40.7%$188.35M$35.84M-0.74230
KALA
KALA BIO
3.4674 of 5 stars
$4.85
+5.0%
$13.50
+178.4%
-24.2%$31.29MN/A-0.5930News Coverage
MRNA
Moderna
4.374 of 5 stars
$27.53
+1.4%
$46.61
+69.3%
-72.1%$10.65B$3.24B-3.155,800Gap Up
NTLA
Intellia Therapeutics
4.6944 of 5 stars
$9.44
-1.3%
$33.37
+253.5%
-51.5%$977.80M$57.88M-1.80600
VRTX
Vertex Pharmaceuticals
4.3458 of 5 stars
$444.51
+0.7%
$511.62
+15.1%
-3.2%$114.15B$11.02B-113.406,100Positive News
ILMN
Illumina
4.8726 of 5 stars
$95.17
+0.4%
$127.39
+33.9%
-7.9%$15.07B$4.37B-15.689,030Positive News
Analyst Forecast
GMAB
Genmab A/S
4.0088 of 5 stars
$20.56
+0.3%
$37.60
+82.9%
-16.6%$13.18B$3.12B11.682,682Analyst Forecast

Related Companies and Tools


This page (NASDAQ:CRSP) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners